- Home
- PHAT vs ATXS Comparison
PHAT vs ATXS Comparison
Compare PHAT & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- ATXS
- Stock Information
- Founded
- PHAT 2018
- ATXS 2008
- Country
- PHAT United States
- ATXS United States
- Employees
- PHAT N/A
- ATXS N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- PHAT Health Care
- ATXS Health Care
- Exchange
- PHAT Nasdaq
- ATXS Nasdaq
- Market Cap
- PHAT 423.4M
- ATXS 401.2M
- IPO Year
- PHAT 2019
- ATXS 2015
- Fundamental
- Price
- PHAT $5.12
- ATXS $5.40
- Analyst Decision
- PHAT Strong Buy
- ATXS Strong Buy
- Analyst Count
- PHAT 4
- ATXS 5
- Target Price
- PHAT $23.00
- ATXS $26.60
- AVG Volume (30 Days)
- PHAT 1.5M
- ATXS 285.8K
- Earning Date
- PHAT 03-06-2025
- ATXS 03-11-2025
- Dividend Yield
- PHAT N/A
- ATXS N/A
- EPS Growth
- PHAT N/A
- ATXS N/A
- EPS
- PHAT N/A
- ATXS N/A
- Revenue
- PHAT $55,252,000.00
- ATXS N/A
- Revenue This Year
- PHAT $202.16
- ATXS N/A
- Revenue Next Year
- PHAT $113.86
- ATXS N/A
- P/E Ratio
- PHAT N/A
- ATXS N/A
- Revenue Growth
- PHAT 8001.47
- ATXS N/A
- 52 Week Low
- PHAT $4.07
- ATXS $5.24
- 52 Week High
- PHAT $19.71
- ATXS $13.33
- Technical
- Relative Strength Index (RSI)
- PHAT 41.95
- ATXS 30.54
- Support Level
- PHAT $6.03
- ATXS $5.89
- Resistance Level
- PHAT $6.89
- ATXS $6.52
- Average True Range (ATR)
- PHAT 0.58
- ATXS 0.37
- MACD
- PHAT 0.05
- ATXS -0.07
- Stochastic Oscillator
- PHAT 37.23
- ATXS 7.80
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.